Almac to Enhance Global Digital Cold Chain Supply for Clinical Trial Materials, Based on £1.1 Billion in Revenue
Optimizing Clinical Supply Chains, Starting with Protocol Design
The supply strategy for Investigational Medicinal Products (IMPs) involves a complex process that goes beyond simply delivering drugs. Almac Clinical Services participates from the early stages of clinical trial protocol design, establishing optimal packaging and qualified temperature-controlled packaging solutions. This proactive approach aims to prevent potential risks of clinical trial delays caused by failures in early supply planning, especially as clinical trial designs become more sophisticated and the proportion of high-value biologics increases. By collaborating early with clinical operations, Almac ensures flexibility in setting expiration dates and managing inventory, leading to significant cost reductions in clinical trials.
Global Cold Chain Real-Time Tracking System Based on Digital Technology
The importance of a global logistics platform that integrates advanced IT technology is increasing to ensure the rapid and safe delivery of drugs to clinical sites worldwide. Almac strictly adheres to Good Distribution Practice (GDP) and utilizes real-time temperature and location tracking sensors to immediately respond to potential adverse weather conditions or physical impacts during transportation. This thorough monitoring is essential for maintaining the integrity of advanced therapy medicinal products (ATMPs), such as cell therapies and gene therapies, which are particularly sensitive to temperature. By ensuring data reliability, Almac plays a crucial role in raising the quality standards of clinical trials.
Expansion of Decentralized Clinical Trials and Patient-Centric Delivery Innovation
One of the biggest changes in the pharmaceutical and biotechnology industry is the rapid expansion of decentralized clinical trials (DCTs), where patients participate without directly visiting healthcare facilities. Almac is keeping pace with this trend by significantly strengthening its direct-to-patient (DtP) service capabilities, delivering IMPs directly to patients' homes. By maximizing patient convenience in clinical trial participation, Almac reduces patient dropout rates and enables the rapid recruitment of diverse patient populations, creating significant business value. This approach ultimately aims to improve patient adherence and the accuracy of clinical data.
Strong Market Competitiveness and Continued Revenue Growth for a Non-Listed Company
Almac Group, a non-listed CDMO company, has demonstrated strong financial stability, exceeding £1.1 billion (approximately ₩1.9 trillion) in annual revenue for the 2025 fiscal year. This represents a growth of approximately 7% compared to the £1.027 billion in the 2024 fiscal year, putting it on par with listed competitors such as Thermo Fisher Scientific's Fisher Clinical Services and Catalent. With the global clinical trial supply and logistics market estimated at $4.6 billion to $5.7 billion in 2025 and expected to continue growing at an annual rate of 7-9%, Almac's unique positioning demonstrates sustainable investment value in the long term.
The global clinical trial supply and logistics market is expected to grow from approximately $4.6 billion in 2025 to over $8.4 billion in 2033, indicating that logistics optimization across the entire drug development lifecycle is essential. With annual revenue of £1.1 billion, Almac has established a unique position in the market, competing with giants like Thermo Fisher Scientific by focusing on direct-to-patient delivery and cold chain technology, which are key components of decentralized clinical trials. In the short term, Almac is optimizing supply chains for early-phase (Phase 1/2) trials, particularly for biologics, to shorten development timelines. In the long term, it is solidifying its market dominance by diversifying its logistics network in line with global regulatory standards. Researchers and pharmaceutical industry professionals are adopting this type of specialized partnership from the clinical design stage to reduce clinical trial failure rates. From an investment perspective, Almac's business model, as a non-listed company, serves as a key indicator of the robust demand in the CDMO market.